Floatz logo

Blinatumomab

B-Cell Acute Lymphoblastic Leukemia

SWOG Cancer Research Networkmonoclonal_antibodyPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Etoposide
University of Washington
Phase 3BBB
Vincristine Sulfate
City of Hope Medical Center
Phase 3BB
Crisantaspase
City of Hope Medical Center
Phase 3BB
Nivestim
University of Washington
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active
BBB
Indicative · Phase 3
72 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →